GlassScriptPhysician profile
Hector Hugo Gonzalez
NPI 1629500129
$12,122.66
in general payments reported to CMS, 2019-2025
20 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $51.56 · 2021: $36.71 · 2022: $243 · 2023: $444 · 2024: $1,177 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $3,847 · Travel and Lodging: $552 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $3,846.64 |
| Travel and Lodging | $552.36 |
| Education | $192.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,422.99 | 2024-2025 | |
| Janssen Biotech, INC. | $883.11 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $776.33 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $354.57 | 2020-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $298.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.01 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $238.93 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $154.96 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $148.38 | 2024-2025 | Voquezna |
| Celgene Corporation | $144.76 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $107.99 | 2025 | Omvoh |
| Pfizer INC. | $77.10 | 2025 | |
| Aimmune Therapeutics, INC. | $65.51 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $40.61 | 2023-2024 | Dificid |
| Novo Nordisk INC | $32.27 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $31.08 | 2020 | |
| Redhill Biopharma INC. | $22.82 | 2022 | |
| Gilead Sciences, INC. | $16.95 | 2024 | |
| Evoke Pharma, INC. | $15.96 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $5.37 | 2023 | Jumbo Biopsy Forcep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.